Huang Jianwen

黄建雯

Areas of Practice

She is the director-in-chief of KWM Belt & Road Center for International Cooperation and Facilitation (BRCICF) and a leading partner in KWM’s healthcare group. Ms. Huang specializes in investments (including inbound and outbound investment), M&A (including domestic and cross-border M&A), and general corporate matters. Ms. Huang acts for clients from varied industry backgrounds for their M&A transactions and general corporate matters.  The industries include pharmaceutical, medical, medical devices, food (including health food), agricultural products, cosmetics, direct marketing, clean energy (solar, wind and nuclear energy), machinery manufacturing, aerospace, mining, ports, and telecommunications, etc.

The Belt & Road

Ms. Huang is in a position to provided accretive legal advice and services on complicated cross-border legal issues for clients based on her perennial experience in international transactions, the thorough understanding of the business and needs of enterprises, and the comprehension of the diversiform legal systems in different countries.  She has provided legal services for numerous investments and M&A projects in various countries along the Belt and Road, including many Asian, African, North American, Oceanian, and European countries such as Laos, Kyrgyzstan, Kazakhstan, Russia, Pakistan, India, Bahrain, Germany, the United Kingdom, Austria, Norway, Sweden, the United States of America, Mexico, Australia, Canada, Namibia, and Zimbabwe, etc.

Pharmaceutical and Healthcare

As the leading partner of the KWM healthcare group, Ms. Huang has acted for a number of domestic and multinational pharmaceutical companies, medical device companies, medical institution investors, and medical institutions with restructuring and reforming, setting up, investment, mergers, daily operations, hospital management consultancy and obtaining all types of relevant approvals (such as, product listed licensing, production and sales license).  Ms. Huang has also assisted with the liaison with the China Food and Drug Administration and the National Health and Family Planning Commission of the People’s Republic of China.  Ms. Huang is familiar with the regulatory supervision and registration requirements of drugs, medical devices, food, and cosmetics in China, and served as an expert witness regarding Chinese legal matters and provided opinions on Chinese laws in several oversea litigations involving health food.  Ms. Huang pays close attention to the latest developments in laws and regulations in medicine and medical related industries.  She is actively involved in the provision of legislative proposals, and is actively engaged with the relevant pharmaceutical industry association to provide legal consultancy services.

In 2018, she acted as the leading partner for Luye Pharma Group on its transaction with AstraZeneca relating to the sale of assets and rights of license in 51 international markets, which was selected as Top 10 Cross-Border M&A Deals in the Field of Healthcare in the Year of 2018.  Additionally, Ms. Huang represented Pfizer for Pfizer’s acquisition project, which was awarded the Cross-Border Deal of the Year and the Healthcare/Life Science Deal of the Year by M&A Advisor in 2010.

Investment and M&A

Ms. Huang has accumulated extensive experience in investment and M&A, and provided legal services to many multinational companies (including Fortune 500 companies), domestic companies, and state owned enterprises (SOEs) for their domestic investment and M&A projects.  Her legal services include complete architectural design of the investment and M&A transactions, due diligence, drafting and modifying transaction documents, negotiation, and assisting liaison with the government and assisting in the assessment and the approval of the governmental process.  Ms. Huang’s many years of professional experience has helped her familiarize herself with different operation models, management models and philosophies of companies.  This helps her to provide the best advice to her clients for their M&A deals.  One of her representative matter is acting as GE’s counsel with respect to Chinese law in GE’s acquisition of Alstom’s power and grid business, which is the biggest M&A deal in 2015 in the industry and the biggest industrial investment GE has ever made.

In addition, Ms. Huang has acted for various SOEs and domestic companies in multiple outbound investment and M&A projects (including North America, Central Asia, Australia, Europe, and Africa, etc.), including acting as the leading counsel and successfully coordinating with attorneys from several countries and regions and different jurisdictions in completing outbound investment and M&A deals involving complicated transaction structure, tight timeline, complex approval process, and different types of target entity.  One of her representative matters is representing an SOE for a series of cross-border acquisition including publicly traded companies in England and Australia and African subsidiaries.  This acquisition is the second biggest acquisition project in the global mining industry in that year.

General Corporate Matters

Ms. Huang understands the commercial interests of different clients and their corporate governance needs.  She provides her clients with customized solutions specifically tailored to address corporate establishment, operations, or liquidation issues.  Her legal expertise includes, but not limited to the following: providing guidance regarding corporate governance structures and the relevant legal risk controls; advising on the laws and regulations in various industries; drafting, revising, and negotiating different types of contracts; communicating with the relevant government authorities with respect to specific business content; and assisting her clients with obtaining government approvals, as well as providing consultation for legal issues with respect to her clients’ daily operations. 

Publications

Ms. Huang authored a number of published works and articles related to foreign investment, cross-border investment, M&A, and the pharmaceuticals and healthcare industry.  

Ms. Huang is a contributing author to the following books/publications: 

(1) Foreign Investment Regulation Review: the first edition, the second edition, the fifth edition and the sixth edition;

(2) Pharmaceuticals and the Law, A Guide to the Chinese Pharmaceuticals and Healthcare Market;

(3) European Lawyer Reference - Distribution and Marketing of Drugs: the 2013 First Edition and the 2015 Second Edition; and

(4) The Health & Aged Care Services section in One Agreement, Many Winners - A Guide to the China-Australia Free Trade Agreement (ChAFTA) (by the Chinese Consulate to Brisbane, Australia and KWM).

Ms. Huang has also published the following: 

(1) “The Policies of Hainan's Pharmaceutical and Healthcare Industry” (Lexis Practical Guidance In-house Legal, June 19, 2018);

(2) “Analysis on the Drugs Administration Law (Draft for Consultation)”(American Chamber of Commerce in China – Weekly Chinese Policy Updates, November 3, 2017);

(3) “Analysis on the Drugs Administration Law (Draft for Consultation)”(KWM China Law Insight, October, 2017);

(4) “The Drug Marketing Authorization Holder Mechanism: Moving Forward through Exploration” (China Legal Review, June 2016); 

(5) “Registration and Record Filing of Health Foods Measures” (American Chamber of Commerce in China – Weekly Chinese Policy Updates, March 8, 2016); 
(6) "Barriers Lifted for Foreign Projects" (China Law and Practice, November/December 2014); 

(7) “How to Correctly Understand the Reform of Registered Capital Registration System” (China Industry & Commerce News, May 29, 2014); 

(8) "The Befuddling Aspects of Chinese Outbound Transactions in the Eyes of non-Chinese Parties" (Asian-Mena Counsel, 2013, Volume 1 Issue 7); and
(9) "Recent Trends in China's Pharmaceutical Industry" (Asia Legal Business – China November 2012).

In addition, Ms. Huang has published a series of articles through the KWM China Law Insight blog and the KWM WeChat platform, which focus on corporate law, foreign investment, food, health food, drugs, medical devices, cosmetics and medical treatment related laws, regulations, and policies analysis in the health care industry. 

Ms. Huang is recognized as one of the “Top 1000 Lawyers of Foreign-Related Affairs” by the Ministry of Justice of PRC.  She is identified as a leading individual in the field of Healthcare & Life Sciences in the year of 2019 by Legal 500.  She is identified as a Tier 1 lawyer in the field of Healthcare & Life Sciences in the year of 2018 and 2019 by Legal Band.  She was identified as a highly recommended lawyer in the field of Healthcare & Life Sciences in the year of 2017 by Legal 500 and was identified as a highly recommended lawyer in the field of corporate and M&A in the year of 2015 by Legal 500.  She was also recognized as one of the 2017 A-List China’s Top 100 lawyers by China Business Law Journal.  Moreover, she was recognized as one of the Top 10 Lawyers Returning to China after Overseas Study by the Beijing Bar Association in 2011.  She has also received multiple KWM awards, including the 2015 Outstanding Cross-border Cooperation of the Year; the 2012 Outstanding Partner of the Year Award; the 2010 Outstanding Partner Award; and the 2006 Outstanding Lawyer Award. 

Work experience

Ms. Huang is a Chinese qualified lawyer. Her working languages are Chinese and English.

Ms. Huang joined KWM in 2003.  Prior to joining KWM, she was a lecturer (corporate law) at Beijing Economics and Trade University School of Law.  

Ms. Huang obtained her LL.M. from New York University School of Law in the U.S., and her Master of Philosophy in Law (M. Phil) from City University of Hong Kong.  She was also a visiting scholar at Harvard Law School.


Location

Legal insights

Stay Focused on the Policies of Hainan's Pharmaceutical and Healthcare Industry.

13 June 2018

The Draft incorporates and reflects material contents in the reform of drugs field in recent years.

31 October 2017

The Decisions has a significant impact on pharmaceutical companies.

16 October 2017

Comparison between the New and Old Catalogue for the Guidance of Foreign Investment Industries.

07 July 2017

This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

For more information on which cookies we use then please refer to our Cookie Policy.